From Burger King to McDonald’s: Fast-Food Prices Surge Dramatically in Recent Years 
Shanghai's Data Policy Shift Could Propel Tesla's Local Data Center Efforts 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
BYD Launches Shark Hybrid Pickup in Mexico, Eyes New Factory Amid US Tariff Hike 
Nike vs. Adidas: Anthony Edwards’ and Wembanyama’s Sneakers Soar in Popularity 
Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
Dolly Parton Serves Up Sweetness with Krispy Kreme Collaboration 
Skepta and PUMA Launch Groundbreaking Collection 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
Burger King Introduces Mozzarella Fries: A New Spin on an Old Favorite 
Burger King’s Largest Franchisee Carrols, Acquired by RBI for $1 Billion, $500M Revamp 
How supermarkets are changing their branding to make you think they’re cheaper 
HEIDELBERG, Germany, May 17, 2016 -- Affimed (Nasdaq:AFMD) today announced that Dr. Adi Hoess, CEO, will present a corporate overview at the UBS Global Healthcare Conference – New York, to be held May 23-25, 2016.
Dr. Hoess' presentation will take place May 23, 1:00-1:30 p.m. (ET).
To access a simultaneous webcast of Dr. Hoess' presentation online, log on to https://cc.talkpoint.com/ubsx001/052316a_ae/?entity=78_BOOCR44 or go to the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php.
A replay of the webcast will be available from Affimed's website for 30 days following the conference. Dr. Hoess' presentation will be available for download in PDF format immediately following the conference presentation in the "Events" section of the Media page of Affimed's website at http://www.affimed.com/events.php.
About Affimed N.V.
Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
CONTACT: IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications
Phone: +49 6221 64793341
E-Mail: [email protected]
